CAS: 17814-85-6; (4-Carboxybutyl)Triphenylphosphonium Bromide

上下游产品

CAS号17814-85-6 4-羧丁基三苯基溴化磷 | CAS号115266-73-4 benzyl ((1R,2R,... | CAS号75040-20-9 3-exo-allylnorc... | CAS号115266-70-1 (1S,2S,3S,4R)-3... | CAS号115266-71-2 2-exo-allyl-3-e... | CAS号107586-16-3 6-(2-°Ct-1-ynyl... | CAS号112375-41-4 methyl (Z)-7-me... | CAS号112375-53-8 methyl (E)-7-me... | CAS号102831-36-7 6-(4-methoxyphe... | CAS号506-32-1 花生四烯酸 | CAS号41639-83-2 拉坦前列腺素(游离酸) | CAS号209860-88-8 他氟前列素酸 | CAS号69552-46-1 碳环素(碳环PGI 2) | CAS号27376-76-7 13,14-dihydro-1... | CAS号2867-63-2 2-苄基环戊酮

(4-(N-Succinimidyl)Carboxybutyl)Triphenylphosphonium Bromide置于维生素 C体系中,用 甲醇,水,二甲基亚砜 用作溶剂,化学反应 96.0H,反应生成4-羧丁基三苯基溴化膦
参考文献:线粒体靶向基团对铂(iv)配合物的反应性和细胞抑制途径的影响
标题:线粒体靶向基团对铂(iv)配合物的反应性和细胞抑制途径的影响
摘要:铂(iv)配合物是顺铂的前药,与铂(II)药物相比具有多种潜在优势.线粒体在产生能量和诱导癌细胞死亡中起关键作用.两种铂(iv)配合物,即c,C,T-[pt(nh 3)2 Cl 2(oh)(ococh 2 Ch 2 Ch 2 Ch 2 Ch 2 Pph 3)] Br和c,C,T-[pt (nh 3)2 Cl 2(ococh 2 Ch 2 Ch 2 Ch 2 Pph 3)2 ] Br 2旨在研究线粒体靶向基团对铂(iv)配合物的生物活性和细胞毒性的影响.通过电喷雾电离质谱,反相高效液相色谱和多核(1 H,13 C,31 P和195Pt)NMR光谱.三苯基phosph靶向基团的引入显着影响pt(iv)配合物的反应性和细胞毒性.与顺铂相比,靶向复合物对线粒体显示出更强的破坏作用,但对癌细胞的抑制作用却较小.靶向组增强了pt(iv)复合物的亲脂性,同时降低了它们对dna的反应性.结果,线粒体形
Doi:10.1021/acs.Inorgchem.8B01707

专利信息

专利号:US-3992439-A
优先权日:1972-04-17
标 题:Synthesis of prostaglandins of the 'one'-series
发明人：SCHAAF THOMAS K; COREY ELIAS J
权利人:PFIZER
摘要:In the synthesis of prostaglandins of the 'one' -series an alteration in the conventional reaction sequence avoids side reactions and provides an improved synthesis via a series of novel intermediates. In this improved synthesis the side chain at the 8 position is attached to the five membered ring before the side chain at the 12 position is attached.

专利号:US-8513441-B2
优先权日:2008-08-29
标题:Prostaglandin synthesis and intermediates for use therein
发明人：ALBERICO DINO; CLAYTON JOSHUA; GORIN BORIS IVANOVICH; OUDENES JAN
权利人:ALBERICO DINO; CLAYTON JOSHUA; GORIN BORIS IVANOVICH; OUDENES JAN; ALPHORA RES INC
摘要:Fused cyclopentane-4-substituted 3,5-dioxalane lactone compounds useful as an intermediate in the synthesis of prostaglandin analogs are provided. The compounds have the formula A: n nwherein R represents an aryl group such as p-methoxyphenyl.n n This compound can be reacted with a lower alkyl aluminum compound to open the dioxalane ring and reduce the lactone to lactol, without over-reducing to diol. The resulting compound can be functionalized to insert chemical side groups of target prostaglandins, adding the required α-side chain and then the required ω-side chain sequentially and independently of each other. The compounds and process are particularly suitable for preparing lubiprostone.

专利号:US-3952033-A
优先权日:1975-04-23
标题 :Furan intermediates and process for synthesis of 4-hydroxycyclopetenones, prostaglandin synthesis intermediates
发明人：FLOYD JR MIDDLETON BRAWNER
权利人:AMERICAN CYANAMID CO
摘要:This disclosure describes novel 2,5-dihydro-2,5-dialkoxyfuran derivatives useful as intermediates for the preparation of the natural prostaglandins and their congeners.

专利号:WO-2023137518-A1
优先权日:2022-01-21
标题 :Platinum complexes
发明人：ALDRICH-WRIGHT JANICE; GORDON CHRISTOPHER; DEO KRISHANT M; KHOURY ALEEN; MCGHIE BRONDWYN; APUTEN ANGELICO; PLATTEN-MENTI MARIA; RASHID FATIN; JURISINEC ASHLEY; SOLIMAN SARAH
权利人:WESTERN SYDNEY UNIV
摘要:The present disclosure relates to platinum complexes, and in particular platinum(II) and platinum(IV) complexes. The present disclosure also relates to synthesis of the platinum complexes, and to intermediates for the synthesis of the platinum complexes. The present disclosure also relates to methods and use of the platinum complexes for treating cancer.

专利号:CN-1345323-A
优先权日:1999-04-12
标题:A new intermediate for the synthesis of prostaglandins

专利号:US-4309351-A
优先权日:1970-07-09
标 题 :Chemical synthesis
发明人：FRIED JOSEF
权利人:UNIV CHICAGO
摘要:This invention relates to compounds of the formulae ##STR1## wherein n is an integer from 2 to 5; M is H, acyl, lower alkyl, or lower alkoxy alkyl; Q is H or lower alkyl; R is alkyl, alkenyl or analkyl; A is H; Y is OH, acyloxy or alkoxy, and when taken together, Y and A is oxo (Oâ•?), and to novel intermediates therefore.